AI promises big gains – but poor data foundations are holding pharma back
Artificial Intelligence (AI) is no longer a distant ambition for life sciences—it’s a present-day necessity. Commercial teams expect AI to deliver smarter targeting, faster insights, and more personalised engagement. Industry surveys reflect this optimism: most leaders anticipate measurable gains in sales and efficiency.
Yet the same research reveals a sobering truth: AI initiatives are failing because the data isn’t ready. Nearly all respondents admit their data is not structured for AI, and many have abandoned projects entirely due to poor quality and fragmentation. The message is clear: AI cannot scale on fractured foundations.
Why data readiness matters more than algorithms
AI models are only as strong as the data they ingest. When data is incomplete, inconsistent, or outdated:
- Predictions lose credibility.
- Field teams distrust recommendations and revert to intuition.
- Analytics cycles slow under the weight of manual cleansing and reconciliation.
Conversely, when data is accurate, harmonised, and accessible, AI can deliver on its promise—driving confident decisions across launch planning, targeting, and omnichannel engagement.
What healthcare data must have to be AI-ready
To move from pilots to enterprise-scale AI, healthcare data needs:
1. High Quality, Currency & Stability
Accurate, validated records with continuous refresh to reflect real-world changes – and maintained consistency over time to ensure longitudinal reliability.
2. Standardisation and Harmonisation
Unified definitions, coding standards, and global-to-local mapping to eliminate costly remapping.
3. Connected, Longitudinal Views
Patient-level claims linked to other patient touchpoints (reimbursement HUB, copay programs, outreach programs), potential blind spots (specialty pharmacy) and treatment related influences (HCP/HCO reference) for a complete picture.
4. Accessibility and Interoperability
Frictionless delivery in ML-ready formats—no operational bottlenecks.
5. Transparency and Governance
Provenance, QA flags, and bias monitoring to sustain trust in production models.
6. Feature Engineering Readiness
Pre-derived measures and event timestamps aligned to commercial AI use cases.
The Industry consensus
Recent findings underscore the same point: building a standardised, connected data foundation is the single most important enabler of AI at scale. Without it, even the most advanced algorithms will fail to deliver meaningful impact.
Why? Because AI thrives on consistency and context. Fragmented datasets force teams into endless cycles of cleansing, mapping, and reconciliation—delays that erode speed to insight and confidence in outputs. A unified foundation eliminates these bottlenecks, enabling seamless integration of claims, HCP/HCO reference, specialty and other data. This isn’t just a technical upgrade; it’s a strategic necessity. Organisations that invest in harmonised, interoperable data today will be the ones able to operationalise AI tomorrow—turning ambition into measurable commercial advantage.
Creating an AI-ready data foundation for life sciences
Symphony Health, an ICON plc company, provides the data foundation AI needs to thrive. Transparency is not just a principle—it’s the cornerstone of scalable AI. Without clear provenance and trust in the underlying data, even the most advanced algorithms fail to deliver meaningful impact. That’s why our approach prioritises a direct connection to the data’s origin. By working closely with primary data providers, we minimise layers of intermediaries, ensuring a stable, reliable pipeline that supports AI-ready integration. In addition, Symphony’s data strategy includes intentional overlap across sources to reinforce consistency and stability over time – so insights remain dependable as your AI models scale from pilot to enterprise.
Our commitment goes beyond raw figures; we deliver clarity, context, and pre-structured insights designed for machine learning workflows. This means our clients can move faster from data to decision—confident that their AI models are powered by accurate, harmonised, and fully governed data.
Standardisation for AI-ready data
AI models demand consistency—without it, even the most advanced algorithms struggle to scale. Symphony Health ensures that every dataset adheres to industry-standard frameworks, enabling seamless interoperability across platforms and data sources. Our data is normalised using globally recognised coding systems, including ICD-10, NDC, and CPT, so your analytics and machine learning workflows start with a common language. We also maintain consistent patient and provider identifiers across claims, reference, and specialty datasets, eliminating the costly remapping and reconciliation that slows AI deployment. By delivering harmonised, standards-based data, Symphony provides the foundation for accurate feature engineering, faster model training, and scalable AI initiatives that work across brands and regions.
Ensuring Fairness and Representativeness
AI models are only as fair and accurate as the data they learn from. If patient populations are skewed or under-represented, predictions can mislead and strategies can fail. Symphony Health tackles this challenge by delivering datasets that reflect diverse patient demographics across geographies, care settings, and therapeutic areas—ensuring models capture real-world complexity rather than narrow slices of the market. Every dataset includes documented provenance and clear limitations, giving data scientists transparency into source composition and confidence in model training. Combined with continuous governance and bias monitoring, Symphony’s approach helps pharmaceutical companies build AI solutions that are not only scalable but equitable, reducing risk and improving decision quality across commercial and clinical applications.
Integrated, Privacy-Preserving Linkage through Synoma®
Unlocking AI’s full potential starts with connected data—and that’s exactly what Synoma® from Symphony Health delivers. With validated tokens achieving 95%+ patient match rates, Synoma enables secure, privacy-preserving linkage across healthcare and consumer datasets, creating longitudinal patient views essential for predictive modelling and advanced analytics. Backed by 20+ years of data integration expertise and excellence and over 40 billion transactions processed annually, Synoma transforms fragmented data into a unified, AI-ready foundation—so life sciences organisations can train models with confidence and scale commercial AI initiatives without compromise.
Cloud-Ready, ML-Friendly Delivery
Symphony Health delivers curated datasets engineered for AI from the ground up. Our data packages are cloud-ready and structured in ML-friendly formats such as Snowflake, but also in Parquet and CSV, ensuring seamless integration into any data lakes and machine learning pipelines. Each dataset includes full lineage, precise timestamps, and pre-derived features—such as treatment sequences, adherence metrics, and NBRx signals—so data scientists can accelerate model training without spending weeks on wrangling and feature engineering. By reducing operational friction and providing harmonised, interoperable data, Symphony enables organisations to move from ingestion to insight faster, powering predictive models and advanced analytics that scale across brands and geographies.
From ambition to action: Building the data backbone for AI
AI won’t scale on fractured foundations. The future of commercial AI depends on more than algorithms—it depends on the integrity, connectivity, and readiness of the data feeding those models. Without a unified, high-quality data backbone, organisations face delays, distrust, and abandoned initiatives. The path forward is clear: partner with providers who deliver consistent, harmonised, and interoperable data that is AI-ready from day one. Symphony Health offers exactly that foundation—curated, cloud-ready datasets with full lineage, timestamps, and pre-derived features designed for machine learning workflows. By eliminating fragmentation and accelerating integration, we help life sciences companies move beyond pilots to scalable AI programmes that drive measurable impact across brands, regions, and channels.
For more about how Symphony Health, an ICON plc company, can assess and support your AI readiness, connect with us today.
In this section
-
Digital Disruption
-
Clinical strategies to optimise SaMD for treating mental health
-
Digital Disruption: Surveying the industry's evolving landscape
- AI and clinical trials
-
Clinical trial data anonymisation and data sharing
-
Clinical Trial Tokenisation
-
Closing the evidence gap: The value of digital health technologies in supporting drug reimbursement decisions
- mHealth wearables
-
Personalising Digital Health
- Real World Data
-
The triad of trust: Navigating real-world healthcare data integration
-
Decoding AI in software as a medical device (SaMD)
- Software as a medical device (SaMD)
-
Clinical strategies to optimise SaMD for treating mental health
-
Patient Centricity
-
Accelerating clinical development through DHTs
-
Agile Clinical Monitoring
-
Capturing the voice of the patient in clinical trials
-
Charting the Managed Access Program Landscape
- Representation and inclusion in clinical trials
-
Exploring the patient perspective from different angles
-
Patient safety and pharmacovigilance
-
A guide to safety data migrations
-
Taking safety reporting to the next level with automation
-
Outsourced Pharmacovigilance Affiliate Solution
-
The evolution of the Pharmacovigilance System Master File: Benefits, challenges, and opportunities
-
Sponsor and CRO pharmacovigilance and safety alliances
-
Understanding the Periodic Benefit-Risk Evaluation Report
-
A guide to safety data migrations
-
Patient voice survey
-
Patient Voice Survey - Decentralised and Hybrid Trials
-
Reimagining Patient-Centricity with the Internet of Medical Things (IoMT)
-
Using longitudinal qualitative research to capture the patient voice
-
Prioritising patient-centred research for regulatory approval
-
Accelerating clinical development through DHTs
-
Regulatory Intelligence
-
Accelerating access
-
Meeting requirements for Joint Clinical Assessments
-
Navigating the regulatory landscape in the US and Japan:
-
Preparing for ICH GCP E6(R3) implementation
-
An innovative approach to rare disease clinical development
- EU Clinical Trials Regulation
-
Using innovative tools and lean writing processes to accelerate regulatory document writing
-
Current overview of data sharing within clinical trial transparency
-
Global Agency Meetings: A collaborative approach to drug development
-
Keeping the end in mind: key considerations for creating plain language summaries
-
Navigating orphan drug development from early phase to marketing authorisation
-
Procedural and regulatory know-how for China biotechs in the EU
-
RACE for Children Act
-
Early engagement and regulatory considerations for biotech
-
Regulatory Intelligence Newsletter
-
Requirements & strategy considerations within clinical trial transparency
-
Spotlight on regulatory reforms in China
-
Demystifying EU CTR, MDR and IVDR
-
Transfer of marketing authorisation
-
Exploring FDA guidance for modern Data Monitoring Committees
-
Streamlining dossier preparation
-
Accelerating access
-
Therapeutics insights
-
Endocrine and Metabolic Disorders
- Cardiovascular
- Cell and Gene Therapies
-
Central Nervous System
-
A mind for digital therapeutics
-
Challenges and opportunities in traumatic brain injury clinical trials
-
Challenges and opportunities in Parkinson’s Disease clinical trials
-
Early, precise and efficient; the methods and technologies advancing Alzheimer’s and Parkinson’s R&D
-
Key Considerations in Chronic Pain Clinical Trials
-
ICON survey report: CNS therapeutic development
-
A mind for digital therapeutics
-
Glycomics
- Infectious Diseases
- NASH
- Obesity
- Oncology
- Paediatrics
-
Respiratory
-
Rare and orphan diseases
-
Advanced therapies for rare diseases
-
Cross-border enrollment of rare disease patients
-
Crossing the finish line: Why effective participation support strategy is critical to trial efficiency and success in rare diseases
-
Diversity, equity and inclusion in rare disease clinical trials
-
Identify and mitigate risks to rare disease clinical programmes
-
Leveraging historical data for use in rare disease trials
-
Natural history studies to improve drug development in rare diseases
-
Patient Centricity in Orphan Drug Development
-
The key to remarkable rare disease registries
-
Therapeutic spotlight: Precision medicine considerations in rare diseases
-
Advanced therapies for rare diseases
-
Endocrine and Metabolic Disorders
-
Transforming Trials
-
Accelerating biotech innovation from discovery to commercialisation
-
Demystifying the Systematic Literature Reviews
-
Ensuring the validity of clinical outcomes assessment (COA) data: The value of rater training
-
From bottlenecks to breakthroughs
-
Linguistic validation of Clinical Outcomes Assessments
-
More than monitoring
-
Optimising biotech funding
- Adaptive clinical trials
-
Best practices to increase engagement with medical and scientific poster content
-
Decentralised clinical trials
-
Biopharma perspective: the promise of decentralised models and diversity in clinical trials
-
Decentralised and Hybrid clinical trials
-
Practical considerations in transitioning to hybrid or decentralised clinical trials
-
Navigating the regulatory labyrinth of technology in decentralised clinical trials
-
Biopharma perspective: the promise of decentralised models and diversity in clinical trials
-
eCOA implementation
-
Blended solutions insights
-
Clinical trials in Japan: An enterprise growth and management strategy
-
How investments in supply of CRAs is better than competing with the demand for CRAs
-
The evolution of FSP: not just for large pharma
-
Embracing a blended operating model
-
Observations in outsourcing: Survey results show a blended future
-
Clinical trials in Japan: An enterprise growth and management strategy
-
Implications of COVID-19 on statistical design and analyses of clinical studies
-
Improving pharma R&D efficiency
-
Increasing Complexity and Declining ROI in Drug Development
-
Innovation in Clinical Trial Methodologies
- Partnership insights
-
Risk Based Quality Management
-
Transforming the R&D Model to Sustain Growth
-
Accelerating biotech innovation from discovery to commercialisation
-
Value Based Healthcare
-
Strategies for commercialising oncology treatments for young adults
-
US payers and PROs
-
Accelerated early clinical manufacturing
-
Cardiovascular Medical Devices
-
CMS Part D Price Negotiations: Is your drug on the list?
-
COVID-19 navigating global market access
-
Ensuring scientific rigor in external control arms
-
Evidence Synthesis: A solution to sparse evidence, heterogeneous studies, and disconnected networks
-
Health technology assessment
-
Perspectives from US payers
-
ICER’s impact on payer decision making
-
Making Sense of the Biosimilars Market
-
Medical communications in early phase product development
-
Navigating the Challenges and Opportunities of Value Based Healthcare
-
Payer Reliance on ICER and Perceptions on Value Based Pricing
-
Payers Perspectives on Digital Therapeutics
-
Precision Medicine
-
RWE Generation Cross Sectional Studies and Medical Chart Review
-
Survey results: How to engage healthcare decision-makers
-
The affordability hurdle for gene therapies
-
The Role of ICER as an HTA Organisation
-
Integrating openness and precision for competitive advantage
-
Strategies for commercialising oncology treatments for young adults
-
Blog
-
Videos
-
Webinar Channel